Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

and expand upon earlier work which provided an efficacy signal in this type of neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four week duration of the trial.

The second trial is a 500 patient, placebo- and active-controlled trial in PHN. This trial will compare the efficacy and safety of NP-1 vs. gabapentin as well as placebo. This active comparator trial is one of the first such efforts to examine any candidate compound at this scale in neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four week duration of the trial.

EpiCept's Approach to Treating Pain

EpiCept's pain product candidates are designed to topically deliver FDA- approved pain management therapeutics directly to the surface of the skin, thereby blocking the ability of peripheral nerve receptors to transmit pain messages to the brain, providing significant pain relief, with fewer adverse side effects, fewer drug to drug interactions and lower potential for abuse than systemically delivered analgesics.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements incl
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:12/16/2009)... -- Sanofi Pasteur, the vaccines ... that it has entered into an exclusive, ... and commercialize its prophylactic vaccine against ... or MRSA. MRSA are responsible for ... to as multidrug-resistant Staphylococcus aureus ...
(Date:12/16/2009)... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... today announced top-line efficacy and safety results from ... the treatment of Peyronie,s disease. Peyronie,s disease is ... the shaft of the penis, which can distort ... impossible in advanced cases. The Phase 2b study, ...
(Date:12/16/2009)... WOONSOCKET, R.I., Dec. 16 CVS/pharmacy and ... stores are now offering H1N1 vaccine in 20 ... locations priority restrictions for receiving H1N1 vaccines continue, ... to be eligible to receive the shot while ... has been restocked and is available at MinuteClinic ...
Breaking Medicine Technology:Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4Atrial fibrillation in endurance athletes still poses problems for sports cardiologists 49549 1Atrial fibrillation in endurance athletes still poses problems for sports cardiologists 49549 2Atrial fibrillation in endurance athletes still poses problems for sports cardiologists 49549 3METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis 28SPPS 29 12714 1METTLER TOLEDO Introduces an Affordable Reaction Block for Solid Phase Peptide Synthesis 28SPPS 29 12714 2Does Location Affect Kids Weight 3F 49542 1Does Location Affect Kids Weight 3F 49542 2
... a study published in The American Journal of ... Clinic psychiatrist Mark Frye, M.D., attempted to identify what ... to experience treatment-emergent mania (TEM).Bipolar disorder, also known as ... mood instability that can be serious and disabling. The ...
... for Type 2 Diabetes-PLYMOUTH MEETING, Pa., Feb. 10 ... promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), ... lead drug candidate for the treatment of type 2 ... CEO of Genaera, presented data from the first of ...
Other Medicine Technology:Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 2Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder 3Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 3
(Date:12/17/2009)... 17 Researchers from the School of ... in the UK are today,encouraging families worldwide ... Year following concerning research* that shows two-thirds of ... a family (68%), with the,Portuguese being the least ... together. , According to ...
(Date:12/17/2009)... over the past three years and what has driven these changes ... ... Morehead, the human capital research firm, will host a webinar titled ... free hour-long webinar will be broadcast on Wednesday, January 27, 2010 ... Morehead’s SVP, Consulting Services and Trevor Byrd, Ph.D., a Morehead Consultant, ...
(Date:12/17/2009)... Healthcare Cost/Risk Analysis reports, activity measures and outcomes reporting to ... toward reduced claim costs and positive return on investment over ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- ... in clinical/claims based cost risk analysis along with personalized nurse ...
(Date:12/16/2009)... -- If proposed health care legislation is enacted, ... insurance system. Approximately 18.4 million Californians and 161 ... upon employer-based insurance for their health care coverage. ... reform legislation entail specific requirements for employer-based insurance. ... for firms that currently comply with most new ...
(Date:12/16/2009)... Annual Gala Raises Significant Funds to Benefit of Children ... Christine Taylor, Gary Cole and Zachary Levi Join ... ,, LOS ANGELES, Dec. 16 At its ... three remarkable individuals. Hasbro President & CEO ... Award in recognition of his far-reaching philanthropic leadership ...
Breaking Medicine News(10 mins):Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5
... Light of New Evidence Showing the,Benefits of UV ... Today, the Indoor,Tanning Association (ITA) launched an ... and criticizing,dermatologists and the sunscreen and cosmetics industries ... advertising blitz begins with a full-page print ad ...
... Md. (March 26, 2008) -- The American Physiological Society ... the 2008 Henry Pickering Bowditch Memorial Award for early-career ... 42 years whose accomplishments are both original and outstanding. ... a professor of pharmacology and toxicology, has focused her ...
... Visiprise, Inc., a leader in,manufacturing execution systems (MES) ... named to START-IT magazine,s START-IT 125 list., ... editors and editorial advisors,of START-IT magazine to recognize ... market., Visiprise,s flagship solution, Visiprise Manufacturing, is ...
... Needed, Experts Say, PHILADELPHIA, March 26 ... group of healthcare leaders based at the,University of ... convene a,special conference to address the national shortage ... cannot be maintained, let alone,expanded, unless we educate ...
... 26 WPCS International,Incorporated (Nasdaq: WPCS ... specialty communication systems and wireless infrastructure, has,announced ... awarded approximately,$12 million in new contracts., ... for The University of,Connecticut, The Mashantucket Pequot ...
... ... BIG HORN, Wyo., March 26 Gourmetceuticals, LLC, ... for use in foods and beverages, today announced ... booster, and,PPL-240, an antioxidant, will be presented at ...
Other Medicine News:Health News:Indoor Tanning Association Launches Campaign Attacking Melanoma Hype 2Health News:MSU professor earns Bowditch Award for work on hypertension 2Health News:MSU professor earns Bowditch Award for work on hypertension 3Health News:Visiprise Named One of the Top Manufacturing Technology Providers 2Health News:Council Calls on White House to Convene Conference on Physician and Nurse Supply 2Health News:WPCS Announces $12 Million in New Projects 2Health News:Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: